How to work in partnership with the LPP
Download as PPTX, PDF0 likes1,015 views
The document discusses how the London Procurement Partnership (LPP) works with NHS organizations in London to manage medicines. It provides an overview of the new NHS landscape and how medicines are managed locally and nationally. It then describes the LPP's pharmacy and medicines workstreams that aim to promote evidence-based, safe, and cost-effective medicine use across primary care, acute/mental health trusts, and cross-sector work. The priorities for these workstreams include procurement, medicines optimization, collaboration, and quality improvement. Dashboards and other tools are used to support stakeholders in improving performance.
How to work in partnership with the LPP
- 1. LPP: How to work in partnership with the LPP Jasbinder Khambh, Pharmacy & Medicines Use & Procurement Lead for Primary Care | NHS London Procurement Partnership
- 2. Managing Medicines in the NHS – London Perspective Jas Khambh Pharmacy & Medicines Use & Procurement Operational Lead & Lead for Primary Care, LPP Tim Root Strategic Pharmaceutical Lead, LPP
- 3. Today’s Objectives •An overview of how medicines are managed in the NHS (in London) •An overview of the Medicines Use and Procurement QIPP Workstreams in London
- 4. The New Landscape •Abolition of PCTs & SHAs •Commissioning power shared between NHS England (was NHS Commissioning Board) and GPs •So we have: NHS England – direct commissioning & oversight of CCG commissioning Clinical commissioning groups – direct commissioning Local authorities: social services, public health services
- 5. Managing medicines •National guidance and priorities • NHS Constitution • Innovation health and wealth • NICE – good practice guidance on developing and updating local formularies (Dec 2012) •Local guidance & priorities • Formularies •Variance across the country • Decision making groups: stakeholder engagement, processes • Criteria for decision making • Decision outputs
- 6. Managing the introduction of new medicines – factors considered •Patient safety •Budget impact •Strength of evidence • Place in therapy • Clinical effectiveness • Cost effectiveness •Equity of access •Stakeholder views
- 7. On the horizon? • Continuing fiscal constraint • Value-based pricing • NHS England contracting for medicines • Greater consistency about commissioning for high-cost PbRX medicines
- 8. Pan-London Management of Medicines through the QIPP agenda •LPP •Built on • 30 years medicines management & medicines procurement expertise in acute trusts • Pharmacy & Medicines Management work of the LPP. •There are 3 workstreams: Primary Care Acute & MH Trusts (Secondary Care) Cross-sector
- 9. 9 Pharmacy & Medicines Use & Procurement Governance Model for London LPP & Medicines Use and Procurement Productivity Steering Group Ad hoc projects / Task & finish group LPP Pharmacy Medicines Management Group/ Secondary care QIPP Sub-Group LPP Steering Board Commercial Board / Productivity PLG at NHSL NHS England Trusts and PCTs QIPP guidance Monthly QIPP reporting Subscriptions Monthly QIPP workstream reporting High level comment on workstream Monthly project reporting against plan Monthly project reporting against plan Primary Care QIPP Sub-Group Project initiation, milestone and results reporting Combined and co- ordinated LPP and productivity reporting
- 10. NHS London Procurement Partnership – Pharmacy, Medicines Use & Procurement Workstream Key Objectives and Priorities for 2013 - 2015 32 CCGS and 3 CSUs QIPP Promotes & supports across the NHS in London: Evidence based choice of medicines Safe , cost-effective use of medicines (£) Reduced medicines waste (£) Recommendations and advice to prescribers and medicines management teams Specialist analytics & informatics support, key performance indicators and dashboards Management of primary care rebate schemes (£) Medicines Optimisation Safe use of medicines and improved quality of patient care: optimised patient experience & treatment outcomes Medicines optimisation as part of routine practice Continuity & quality of care involving medicines use, across the primary/secondary/tertiary/social care interfaces Specialist pharmaceutical support for optimisation of prescribing for complex therapeutic areas such as mental health, cancer chemotherapy , nutrition and dietetics (£) Collaboration and sharing of best practice London-wide stakeholder engagement and working groups Pan-London solutions Do once and share : efficient use of limited resources (£) Facilitated access to key advice & information at www.lpp.nhs.uk (£) Training and education Collaborative working with external stakeholders e.g. pharmaceutical industry Procurement of the most cost-effective medicines for acute & mental health trusts Expert knowledge and specialist expertise from medicines procurement specialists Pan-London contracts to secure best value-for-money (£) Strategic clinical medicines procurement (£) Support for management of expenditure on: high cost PBR excluded drugs (£) supply of medicine through Homecare (£) Patient Access Schemes (£) Acute and Mental Health Trusts Note: All of these objectives aim to improve productivity and quality of patient care. Objectives marked (£) can provide significant financial savings to the local health economy in London. These savings may be quantified in terms of return in investment and against key performance indicators.
- 11. Primary Care QIPP Workstream • Engagement with CCGs/CSUs • Collaborative approach • Primary Care QIPP sub-group • Priority setting • Medicines Information & Specialist Pharmacy Services support • Data collection, analysis & reporting • Dashboards • Rebate schemes
- 12. 2013/14 priorities • Engagement with new stakeholder groups • CCGs, CSUs, NHS England • Quality & Safety • Cross-sector • Extend & Refine data presentation • Split dashboards • Acute & MH Trusts • Define® benchmarking tool • Primary Care • Financial • Quality & safety • Mental Health • Nutrition
- 13. Primary Care Clinical Priorities for 2012/13 Cardiovascular •Renin-angiotensin system drugs •Statins •Ezetimibe Endocrine •Diabetes •Osteoporosis Central Nervous System •Prescribing in mental health •Low dose antipsychotics •Hypnotics •Venlafaxine •Pain control Other Therapeutic areas •Glucosamine •Prednisolone •Wound care •Specials •Vitamin D •Oral nutritional supplements •Antimicrobials
- 14. Tools and resources www.lpp.nhs.uk • Dashboards • KPIs and Red Amber Green ratings • CCG and CSU level (not practice level) • Benchmarked data including savings / lost opportunity • Key messages bulletins with MI • Supporting information for procurement • Newsletters for chief executives • Working groups • Specialist pharmacist advice & tools to support implementation • Events
- 15. LPP website
- 16. LPP website
- 17. Trend graphs for PCTs/Clusters
- 20. Final points • Engagement with the clinical commissioning groups • Understand new stakeholders & their priorities •Support CCGs and Trusts to improve performance • Support local QIPP plans • Share good practice • Pan-London approach • Collaborative working between primary & secondary care • Enhance Dashboards • Collaborative working with community pharmacists • Collaborative working with the pharmaceutical industry